BEIJING, April 2026 — The MedAccred® program, an industry-managed critical process accreditation program administered by the Performance Review Institute (PRI®), is accelerating its global initiative to transform supplier oversight and elevate quality assurance across the medical device industry. This momentum was demonstrated at the 3rd International Nuclear Technology Applications Development Conference (INTAC 2026) and the International Irradiation Association (iia) Roadshow, held April 21–23 in Beijing, China. 

The MedAccred® program’s engagement underscores its expanding global role in advancing standardized, risk-based oversight models for critical manufacturing processes, including sterilization and irradiation technologies that directly impact patient safety, product quality, and regulatory confidence. 

During the opening ceremony, the China Isotope & Radiation Association (CIRA) announced a new initiative, “Initiative on Jointly Building an Open, Inclusive, Universally Beneficial and Win-Win International Industrial Ecosystem for Nuclear Technology Applications,” that calls for international organizations, industry groups, and companies to work collaboratively for the peaceful and inclusive use of nuclear technology. The initiative is designed to strengthen collaboration between Chinese and international stakeholders and accelerate innovation, closely aligning with MedAccred’s mission to drive harmonization of global standards, industry best practices, and scalable supplier assurance frameworks. 

Representing PRI and the MedAccred program, Justin McCabe, Operations and Business Development Manager, participated in the opening ceremony, reflecting the program’s growing influence in global discussions surrounding advanced manufacturing and irradiation technologies. McCabe, alongside Sterilization Lead Staff Engineer Kim Patton, also delivered technical presentations addressing global trends in radiation processing, evolving regulatory expectations, and the increasing need for independent, industry-driven supplier oversight. 

“MedAccred’s participation at INTAC signifies a broader global initiative to align industry around consistent, high-impact oversight models,” stated Justin McCabe. “Through collaboration with international partners, we are helping define a globally connected quality ecosystem that strengthens trust, accelerates innovation, and ensures the highest standards of safety and performance.” 

INTAC 2026 brought together stakeholders from healthcare, industrial processing, environmental applications, and regulatory bodies, reinforcing its role as a leading international forum for nuclear technology applications. The MedAccred program’s participation signals a continued shift toward global integration, bridging regional efforts into a unified approach to supplier quality and critical process assurance.